Prometic Life Sciences Inc., of Laval, Quebec, presented new results from preclinical studies of PBI-4050 in cardiac and lung fibrosis, respiratory function, and lung structural remodeling following a myocardial infarction (MI) induced by coronary artery ligation. Beginning two weeks after the MI, the animals were treated with PBI-4050 for three weeks.